Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | CCKAR | P32238 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22618763 | 0.95 | FOLH1 (0.34) | FOLH1OPRM1NMT2NMT1CCKAR | |
| SCHEMBL27189806 | 0.92 | FOLH1 (0.34) | FOLH1OPRM1NMT2NMT1CCKAR | |
| SCHEMBL27189815 | 0.85 | DGAT1 (0.35) | FOLH1OPRM1CCKARCCKBRDGAT1 | |
| SCHEMBL22618791 | 0.84 | FOLH1 (0.34) | FOLH1OPRM1CCKARCCKBRNPY1R | |
| SCHEMBL26603616 | 0.83 | FOLH1 (0.34) | FOLH1NMT2NMT1DGAT1F2R | |
| SCHEMBL22618790 | 0.82 | FOLH1 (0.30) | FOLH1OPRM1 | |
| SCHEMBL23193003 | 0.81 | FOLH1 (0.35) | FOLH1OPRM1DRD2 | |
| SCHEMBL23193103 | 0.80 | FOLH1 (0.34) | FOLH1OPRM1 | |
| SCHEMBL22561392 | 0.80 | FOLH1 (0.36) | FOLH1OPRM1DGAT1DRD2 | |
| SCHEMBL23193195 | 0.80 | OPRM1 (0.34) | FOLH1OPRM1DRD2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | FOLH1 207/4885OPRM1 4247/4885NMT2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.